Retatrutide 20mg

Retatrutide 20 mg – Triple Hormone Receptor Agonist for Advanced Metabolic Research

Retatrutide 20 mg is an advanced investigational peptide engineered to activate three key metabolic hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and the glucagon receptor. This triple agonist approach represents a major innovation in the field of metabolic therapeutics, providing synergistic effects on appetite regulation, energy expenditure, glucose homeostasis, and body weight reduction.

Retatrutide 20mg, This 20 mg lyophilized formulation is ideal for preclinical and in vitro studies exploring mechanisms of obesity, type 2 diabetes, and related metabolic disorders. Retatrutide has gained significant interest in the scientific community due to its promising results in clinical trials, showing substantial reductions in body weight and improved glycemic control beyond that of single-pathway therapies such as GLP-1 receptor agonists alone.

Mechanism of Action:

Retatrutide 20mg exerts its biological effects by simultaneously engaging:

• GLP-1 Receptor: Enhances insulin secretion, reduces appetite, and delays gastric emptying.

• GIP Receptor: Stimulates insulin release in a glucose-dependent manner and may improve beta-cell function.

• Glucagon Receptor: Increases energy expenditure and promotes fat oxidation.

This multi-receptor targeting offers a comprehensive metabolic effect, influencing both energy intake and output, making it a promising candidate in anti-obesity and diabetes research pipelines.

Product Specifications:

• Name: Retatrutide

• Dosage: 20 mg

• Form: Lyophilized powder

• Purity: ≥98% (HPLC verified)

• Molecular Formula: C₁₈₇H₂₉₄N₅₄O₅₉

• Sequence Type: Synthetic peptide

• Storage: -20°C; protect from light and moisture

• Reconstitution: Sterile water or buffer; vortex gently to fully dissolve

Applications in Research:

• Investigation of weight loss mechanisms and energy balance

• Studies of insulin sensitivity and glucose metabolism

• Exploration of combination receptor agonist therapies

• Development of next-generation anti-obesity or antidiabetic agents

• Evaluation of peptide pharmacokinetics and receptor binding profiles

Why Choose Retatrutide 20 mg for Research?

• Potent multi-agonist activity: Targets three key receptors with high specificity

• Enhanced efficacy over single-pathway agonists

• Ideal for metabolic, endocrine, and obesity research models

• Backed by recent clinical data showing substantial therapeutic promise.